Abstract:BACKGROUND AND AIMS:Fatty acid translocase CD36 (CD36) is a membrane protein with multiple immuno-metabolic functions. Palmitoylation has been suggested to regulate the distribution and functions of CD36, but little is known about its significance in non-alcoholic steatohepatitis (NASH). METHODS:Human liver tissue samples were obtained from patients undergoing liver biopsy for diagnostic purposes. CD36 knockout mice were injected with lentiviral vectors expressing wild-type CD36 or CD36 with mutated palmitoylation sites. Liver histology, immunofluorescence, mRNA expression profile, subcellular distributions and functions of CD36 protein were assessed. RESULTS:The localization of CD36 on the plasma membrane of hepatocytes was markedly increased in patients with NASH compared to patients with normal liver and those with simple steatosis. Increased CD36 palmitoylation and increased localization of CD36 on the plasma membrane of hepatocytes were also observed in livers of mice with NASH. Furthermore, inhibition of CD36 palmitoylation protected mice from developing NASH. The absence of palmitoylation decreased CD36 protein hydrophobicity reducing its localization on the plasma membrane as well as in lipid raft of hepatocytes. Consequently, a lack of palmitoylation decreased fatty acid uptake and CD36/Fyn/Lyn complex in HepG2 cells. Inhibition of CD36 palmitoylation not only ameliorated intracellular lipid accumulation via activation of the AMPK pathway, but also inhibited the inflammatory response through the inhibition of the JNK signaling pathway. CONCLUSIONS:Our findings demonstrate the key role of palmitoylation in regulating CD36 distributions and its functions in NASH. Inhibition of CD36 palmitoylation may represent an effective therapeutic strategy in patients with NASH. LAY SUMMARY:Fatty acid translocase CD36 (CD36) is a multifunctional membrane protein which contributes to the development of liver steatosis. In the present study, we demonstrated that the localization of CD36 on the plasma membrane of hepatocytes is increased in patients with non-alcoholic steatohepatitis. Blocking the palmitoylation of CD36 reduces CD36 distribution in hepatocyte plasma membranes and protects mice from non-alcoholic steatohepatitis. The inhibition of CD36 palmitoylation not only improved fatty acid metabolic disorders but also reduced the inflammatory response in vitro and in vivo. The present study suggests that CD36 palmitoylation is important for non-alcoholic steatohepatitis development and inhibition of CD36 palmitoylation could be used to cure non-alcoholic steatohepatitis.

The Emerging Roles of Fatty Acid Translocase/Cd36 and the Aryl Hydrocarbon Receptor in Fatty Liver Disease

CD36 palmitoylation disrupts free fatty acid metabolism and promotes tissue inflammation in non-alcoholic steatohepatitis.

CD36 Plays a Negative Role in the Regulation of Lipophagy in Hepatocytes Through an AMPK-dependent Pathway

Functional Proteomic Analysis of Nonalcoholic Fatty Liver Disease in Rat Models: Enoyl-coenzyme a Hydratase Down-Regulation Exacerbates Hepatic Steatosis

Hepatic Fatty Acid Transporter Cd36 is a Common Target of LXR, PXR, and PPARgamma in Promoting Steatosis.

Signal Transduction and Molecular Regulation in Fatty Liver Disease

A Novel Role for the Dioxin Receptor in Fatty Acid Metabolism and Hepatic Steatosis.

PXR and LXR in hepatic steatosis: a new dog and an old dog with new tricks.

Inhibition of Fatty Acid Translocase (FAT/CD36) Palmitoylation Enhances Hepatic Fatty Acid beta-Oxidation by Increasing Its Localization to Mitochondria and Interaction with Long-Chain Acyl-CoA Synthetase 1

MicroRNA-20a-5p Ameliorates Non-alcoholic Fatty Liver Disease via Inhibiting the Expression of CD36

Fatty Liver Diseases, Bile Acids, and FXR

CD36, a signaling receptor and fatty acid transporter that regulates immune cell metabolism and fate

Cellular Fatty Acid Uptake: a Pathway under Construction.

Inhibition of fatty acid translocase (FAT/CD36) palmitoylation enhances hepatic fatty acid β-oxidation by increasing its localization to mitochondria and interaction with long-chain acyl-CoA synthetase 1.

Role of CD36 in the formation of non-alcoholic fatty liver disease in mice

Lipid sensing nuclear receptors involved in the pathogenesis of fatty liver disease

CD36 Promotes De Novo Lipogenesis in Hepatocytes Through INSIG2-dependent SREBP1 Processing

Context-specific Fatty Acid Uptake is a Finely-Tuned Multi-Level Effort

CD36 facilitates fatty acid uptake by dynamic palmitoylation-regulated endocytosis

Modulation of xenobiotic nuclear receptors in high-fat diet induced non-alcoholic fatty liver disease

Long-chain fatty acid activates hepatocytes through CD36 mediated oxidative stress